LncRNA CTBP1‐AS inhibits TP63‐mediated activation of S100A14 during prostate cancer progression
Cancer Science · 2024
DOI: 10.1111/cas.16138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Guangzheng Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China. Hauptthemen laut MEDLINE: Cell Proliferation, Disease Progression, Gene Expression Regulation, Neoplastic, Prostatic Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Haiyan Fund.
Abstract (Originalsprache)
Long noncoding RNAs (lncRNAs) have emerged as important molecules and potential new targets for human cancers. This study investigates the function of lncRNA CTBP1 antisense RNA (CTBP1‐AS) in prostate cancer (PCa) and explores the entailed molecular mechanism. Aberrantly expressed genes potentially correlated with PCa progression were probed using integrated bioinformatics analyses. A cohort of 68 patients with PCa was included, and their tumor and para‐cancerous tissues were collected. CTBP1‐AS was highly expressed in PCa tissues and cells and associated with poor patient prognosis. By contrast, tumor protein p63 (TP63) and S100 calcium binding protein A14 (S100A14) were poorly expressed in the PCa tissues and cells. CTBP1‐AS did not affect TP63 expression; however it blocked the TP63‐mediated transcriptional activation of S100A14, thereby reducing its expression. CTBP1‐AS silencing suppressed proliferation, apoptosis resistance, migration, invasion, and tumorigenicity of PCa cell lines, while its overexpression led to inverse results. The malignant phenotype of cells was further weakened by TP63 overexpression but restored following artificial S100A14 silencing. In conclusion, this study demonstrates that CTBP1‐AS plays an oncogenic role in PCa by blocking TP63‐mediated transcriptional activation of S100A14. This may provide insight into the management of PCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
ORCID-Profile: Hui Chen
Förderung
- Haiyan Fund
Zitieren
APA
Wu, G., Dong, Z., Dong, Y., Chen, Y., Zhu, H., Ding, D., Cui, Y., Wang, Y., Xu, Y., & Chen, H. (2024). LncRNA CTBP1‐AS inhibits TP63‐mediated activation of S100A14 during prostate cancer progression. Cancer Science. https://doi.org/10.1111/cas.16138
Vancouver
Wu G, Dong Z, Dong Y, Chen Y, Zhu H, Ding D, et al. LncRNA CTBP1‐AS inhibits TP63‐mediated activation of S100A14 during prostate cancer progression. Cancer Science. 2024. doi:10.1111/cas.16138
BibTeX
@article{Wu2024,
author = {Wu, Guangzheng and Dong, Zhenkun and Dong, Yuhang and Chen, Yinmei and Zhu, Huan and Ding, Dexin and Cui, Yan and Wang, Yiwen and Xu, Yangyang and Chen, Hui},
title = {LncRNA CTBP1‐AS inhibits TP63‐mediated activation of S100A14 during prostate cancer progression},
journal = {Cancer Science},
year = {2024},
doi = {10.1111/cas.16138}
}
EUVIMED